Marathoner Runner Stress Study
Presentation: American College of Nutrition Annual Meeting, Sept 2007
Summary:
In a double-blind, placebo-controlled study, marathon runners taking Wellmune WGP® reported significant physical and psychological health benefits.
Fully 66% fewer subjects reported upper respiratory tract infection URTI symptoms when taking 250 mg of Wellmune WGP daily for four weeks, compared with runners treated with a placebo. The symptoms measured included nasal congestion, runny nose, sore throat, sneezing, cough, fatigue, heache, general malaise and body aches. In addition, study participants taking Wellmune WGP rated their health 44% higher as compared to normal.
In contrast with the placebo group, the Wellmune WGP treatment group reported a:
- 22% increase in vigor
- 48% reduction in fatigue
- 38% reduction in tension
- 38% reduction in stress-related confusion
Study Design:
The double-blind, placebo-controlled study included 75 marathon runners (35 men, 40 women) ages 18-53 (mean age 36 years) who were recruited at the 2007 Carlsbad Marathon in California. Subjects were treated with Wellmune wgp, a natural carbohydrate that activates key immune cells to more quickly recognize and kill foreign challenges, or a placebo for four weeks.
The study measured the psychological states of the participants using a Profile of Mood States (POMS) questionnaire. The POMS profile method, which measures six primary moods states (tension, depression, anger, fatigue, vigor and confusion), has been employed in more than 2,900 health studies.
